[Advances in Prediction and Diagnostic Biomarkers on Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2015 Mar 18

PMID 25778900

Authors

Ziwei Wang

Jianmin Wang

Affiliations

Soon will be listed here.

References

Grimm J, Zeller W, Zander A . Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD. Bone Marrow Transplant. 1998; 21(1):29-32. DOI: 10.1038/sj.bmt.1701041. View

Ferrara J, Levine J, Reddy P, Holler E . Graft-versus-host disease. Lancet. 2009; 373(9674):1550-61. PMC: 2735047. DOI: 10.1016/S0140-6736(09)60237-3. View

Paczesny S, Krijanovski O, Braun T, Choi S, Clouthier S, Kuick R . A biomarker panel for acute graft-versus-host disease. Blood. 2008; 113(2):273-8. PMC: 2615645. DOI: 10.1182/blood-2008-07-167098. View

Socie G, Blazar B . Acute graft-versus-host disease: from the bench to the bedside. Blood. 2009; 114(20):4327-36. PMC: 2777122. DOI: 10.1182/blood-2009-06-204669. View

Weissinger E, Schiffer E, Hertenstein B, Ferrara J, Holler E, Stadler M . Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2007; 109(12):5511-9. DOI: 10.1182/blood-2007-01-069757. View

Holler E, Rogler G, Herfarth H, Brenmoehl J, Wild P, Hahn J . Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood. 2004; 104(3):889-94. DOI: 10.1182/blood-2003-10-3543. View

Paczesny S, Braun T, Levine J, Hogan J, Crawford J, Coffing B . Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010; 2(13):13ra2. PMC: 2895410. DOI: 10.1126/scitranslmed.3000406. View

Bastos Oreiro M, Castilla-Llorente C, de la Guia A, de Paz R, Van Domselaar M, Nieto J . Fecal calprotectin in allogeneic stem cell transplantation for the diagnosis of acute intestinal graft versus host disease. Bone Marrow Transplant. 2012; 47(9):1241-2. DOI: 10.1038/bmt.2011.241. View

Holler E, Rogler G, Brenmoehl J, Hahn J, Greinix H, Dickinson A . The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation. Int J Immunogenet. 2008; 35(4-5):381-4. DOI: 10.1111/j.1744-313X.2008.00795.x. View

10.

Sato M, Nakasone H, Oshima K, Ishihara Y, Wada H, Sakamoto K . Prediction of transplant-related complications by C-reactive protein levels before hematopoietic SCT. Bone Marrow Transplant. 2012; 48(5):698-702. DOI: 10.1038/bmt.2012.193. View

11.

Rodriguez-Otero P, Porcher R, Peffault de Latour R, Contreras M, Bouhnik Y, Xhaard A . Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. Blood. 2012; 119(24):5909-17. DOI: 10.1182/blood-2011-12-397968. View

12.

Fujioka T, Tamaki H, Ikegame K, Yoshihara S, Taniguchi K, Kaida K . Frequency of CD4(+)FOXP3(+) regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD. Bone Marrow Transplant. 2012; 48(6):859-64. DOI: 10.1038/bmt.2012.232. View

13.

Engelhardt B, Sengsayadeth S, Jagasia M, Savani B, Kassim A, Lu P . Tissue-specific regulatory T cells: biomarker for acute graft-vs-host disease and survival. Exp Hematol. 2012; 40(12):974-982.e1. PMC: 3611587. DOI: 10.1016/j.exphem.2012.08.002. View

14.

Levine J, Logan B, Wu J, Alousi A, Bolanos-Meade J, Ferrara J . Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood. 2012; 119(16):3854-60. PMC: 3335389. DOI: 10.1182/blood-2012-01-403063. View

15.

August K, Chiang K, Qayed M, Dulson A, Worthington-White D, Cole C . Relative defects in mucosal immunity predict acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014; 20(7):1056-9. DOI: 10.1016/j.bbmt.2014.03.012. View

16.

Lv M, Ye H, Zhao X, Zhao X, Chang Y, Liu D . Ceruloplasmin is a potential biomarker for aGvHD following allogeneic hematopoietic stem cell transplantation. PLoS One. 2013; 8(3):e58735. PMC: 3591372. DOI: 10.1371/journal.pone.0058735. View

17.

Chaidos A, Patterson S, Szydlo R, Chaudhry M, Dazzi F, Kanfer E . Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood. 2012; 119(21):5030-6. PMC: 6143158. DOI: 10.1182/blood-2011-11-389304. View

18.

Jordan K, Christensen I, Heilmann C, Sengelov H, Muller K . Pretransplant C-reactive protein as A prognostic marker in allogeneic stem cell transplantation. Scand J Immunol. 2013; 79(3):206-13. DOI: 10.1111/sji.12137. View

19.

Mlynarczewska A, Wysoczanska B, Karabon L, Bogunia-Kubik K, Lange A . Lack of IFN-gamma 2/2 homozygous genotype independently of recipient age and intensity of conditioning regimen influences the risk of aGVHD manifestation after HLA-matched sibling haematopoietic stem cell transplantation. Bone Marrow Transplant. 2004; 34(4):339-44. DOI: 10.1038/sj.bmt.1704581. View

20.

Weissinger E, Metzger J, Dobbelstein C, Wolff D, Schleuning M, Kuzmina Z . Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation. Leukemia. 2013; 28(4):842-52. PMC: 7101954. DOI: 10.1038/leu.2013.210. View